<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Benign Prostatic Hyperplasia - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    
    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Benign Prostatic Hyperplasia</span>
        </nav>

        <header class="page-header">
            <h1>Benign Prostatic Hyperplasia</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Complex</span>
                
                
                <span class="badge badge-mondo">
                    <a href="https://monarchinitiative.org/disease/MONDO:0010811" target="_blank">
                        MONDO:0010811
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Urological Disease</span>
                
            </div>
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">9</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">9</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
        </div>

        <!-- Subtypes -->
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">9</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Prostatic Stromal and Epithelial Proliferation</div>
                
                <div class="item-desc">Age-related increase in prostatic stromal and glandular tissue, particularly in the transition zone. Dihydrotestosterone (DHT) drives proliferation through androgen receptors.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Prostatic Epithelial Cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0002231" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">Cell Proliferation</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38654277" target="_blank">PMID:38654277</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Proliferative nodular formation represents a characteristic pathological feature of benign prostatic hyperplasia (BPH) and serves as the primary cause for prostate volume enlargement and consequent lower urinary tract symptoms (LUTS)."</div>
                
                
                <div class="evidence-explanation">This evidence confirms that proliferative nodular formation in the transition zone is the primary pathological feature driving BPH symptoms.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Bladder Outlet Obstruction</div>
                
                <div class="item-desc">Enlarged prostate compresses urethra, increasing resistance to urine flow. Static component from tissue mass and dynamic component from smooth muscle tone.
</div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Detrusor Dysfunction</div>
                
                <div class="item-desc">Chronic obstruction leads to detrusor muscle hypertrophy and later decompensation. Results in overactive bladder symptoms and incomplete emptying.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Smooth Muscle Cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000192" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37827216" target="_blank">PMID:37827216</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Benign prostate hyperplasia (BPH) is caused by the nonmalignant enlargement of the transition zone of the prostate gland, leading to lower urinary tract symptoms."</div>
                
                
                <div class="evidence-explanation">This evidence supports that BPH-related enlargement causes lower urinary tract symptoms through bladder outlet obstruction and detrusor dysfunction.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Androgen-Dependent Growth</div>
                
                <div class="item-desc">DHT converted from testosterone by 5-alpha reductase drives prostatic growth. 5-alpha reductase inhibitors shrink prostate.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">Androgen Response</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Hypoxia-Induced Epithelial-Mesenchymal Transition</div>
                
                <div class="item-desc">Hypoxic basal epithelial cells (BE5) drive nodular formation through upregulation of FOS and activation of EMT signaling, particularly in glandular nodules of the transition zone.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">Epithelial to Mesenchymal Transition</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38654277" target="_blank">PMID:38654277</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"A distinct subgroup of basal epithelial (BE) cells, referred to as BE5, was identified to play a crucial role in driving this progression through the hypoxia-induced epithelial-mesenchymal transition (EMT) signaling pathway."</div>
                
                
                <div class="evidence-explanation">This evidence identifies BE5 cells as key drivers of BPH through hypoxia-induced EMT, establishing a molecular mechanism for nodular formation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">TGF-beta/ROCK1 Mediated Stromal Hyperplasia</div>
                
                <div class="item-desc">Aberrant activation of TGF-beta/ROCK1 pathway recruits mesenchymal stem cells that differentiate into fibroblasts and myofibroblasts, driving stromal hyperplasia and fibrosis.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">TGF-beta Signaling</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38711089" target="_blank">PMID:38711089</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The aberrant activation of transforming growth factor Œ≤ (TGF-Œ≤)/Rho kinase 1 (ROCK1) increased the stemness of BPH tissue by recruiting mesenchymal stem cells (MSCs), indicating the important role of embryonic reawakening in BPH."</div>
                
                
                <div class="evidence-explanation">This evidence demonstrates that TGF-beta/ROCK1 activation drives prostatic stromal hyperplasia through MSC recruitment and differentiation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/39455522" target="_blank">PMID:39455522</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"ROCK1 and ROCK2 were significantly up-regulated in BPH tissues, correlating with clinical parameters."</div>
                
                
                <div class="evidence-explanation">This evidence confirms upregulation of ROCK1/2 in human BPH tissues and their correlation with disease severity.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">ROCK-Mediated Fibrosis and Beta-Catenin Signaling</div>
                
                <div class="item-desc">ROCK1/2 activation promotes fibrosis, EMT, and cell proliferation by stabilizing beta-catenin and activating downstream targets including C-MYC, Snail, and Survivin. ROCK inhibition reverses these processes.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">Wnt Signaling Pathway</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/39455522" target="_blank">PMID:39455522</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"ROCK downregulation inhibited the Œ≤-catenin signaling pathway (such as C-MYC, Snail and Survivin) and decreased Œ≤-catenin protein stability, while inhibiting TGF-Œ≤/Smad2/3 signaling."</div>
                
                
                <div class="evidence-explanation">This evidence shows ROCK signaling converges on beta-catenin pathway to drive BPH pathophysiology, providing a therapeutic target.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Oxidative Stress and Epithelial Plasticity</div>
                
                <div class="item-desc">Low-androgen signaling epithelial populations show increased vulnerability to oxidative stress due to reduced antioxidant defenses. Mitochondrial ROS drives cell proliferation and stemness in BPH.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">Response to Oxidative Stress</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37827216" target="_blank">PMID:37827216</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Pb-PRL mouse prostates exhibited increased vulnerability to oxidative stress due to reduction of antioxidant enzyme expression. One-month treatment of Pb-PRL mice with anethole trithione (ATT), a specific inhibitor of mitochondrial ROS production, reduced prostate weight and voiding frequency."</div>
                
                
                <div class="evidence-explanation">This evidence demonstrates that oxidative stress contributes to BPH progression and that antioxidant therapy can reduce prostate enlargement and symptoms.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Inflammation and IL-6 Signaling</div>
                
                <div class="item-desc">Periodontal pathogens and inflammatory stimuli upregulate IL-6, IL-6R, and gp130, activating the Akt pathway to promote epithelial and stromal proliferation while inhibiting apoptosis.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">Inflammatory Response</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38764065" target="_blank">PMID:38764065</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"P. gingivalis infection promoted prostate cell proliferation, inhibited apoptosis, and upregulated the expression of inflammatory cytokines interleukin-6 (IL-6; 4.47-fold), interleukin-6 receptor-Œ± (IL-6RŒ±; 5.74-fold) and glycoprotein 130 (gp130; 4.47-fold) in prostatic tissue."</div>
                
                
                <div class="evidence-explanation">This evidence links oral-prostate inflammation to BPH progression through IL-6/IL-6R/gp130-mediated Akt signaling, representing a novel pathophysiological axis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Urinary Frequency
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Urological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000012" target="_blank">
                            HP:0000012
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Nocturia
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Urological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000017" target="_blank">
                            HP:0000017
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37827216" target="_blank">PMID:37827216</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"One-month treatment of Pb-PRL mice with anethole trithione (ATT), a specific inhibitor of mitochondrial ROS production, reduced prostate weight and voiding frequency."</div>
                
                
                <div class="evidence-explanation">This evidence shows that voiding frequency (including nocturia) is a key symptom of BPH that can be reduced through therapeutic intervention targeting oxidative stress.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Weak Urinary Stream
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Urological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000016" target="_blank">
                            HP:0000016
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Hesitancy
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Urological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000016" target="_blank">
                            HP:0000016
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Difficulty initiating urination</div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Incomplete Emptying
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Urological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000016" target="_blank">
                            HP:0000016
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Urinary Retention
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Urological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000016" target="_blank">
                            HP:0000016
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Acute retention is emergency</div>
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    SRD5A2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    AR
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    ROCK1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causal)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/39455522" target="_blank">PMID:39455522</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"ROCK1 and ROCK2 were significantly up-regulated in BPH tissues, correlating with clinical parameters."</div>
                
                
                <div class="evidence-explanation">This evidence establishes ROCK1 as causally implicated in BPH pathogenesis through upregulation and correlation with disease severity.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    ROCK2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causal)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/39455522" target="_blank">PMID:39455522</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Y-27632 targeted the inhibition of ROCK1 &amp; ROCK2 expression and inhibited cell proliferation, fibrosis, epithelial-mesenchymal transition (EMT), while induced cell apoptosis in a dose-dependent manner."</div>
                
                
                <div class="evidence-explanation">This evidence demonstrates ROCK2 as a causal factor in BPH through its role in proliferation, fibrosis, and EMT.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    FOS
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causal)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38654277" target="_blank">PMID:38654277</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"A distinguishing characteristic of the BE5 cell subgroup in patients with BPH was its heightened hypoxia and upregulated expression of FOS."</div>
                
                
                <div class="evidence-explanation">This evidence identifies FOS upregulation as a key molecular driver of hypoxia-induced EMT in BPH nodular formation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">9</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Alpha-Blockers
                    
                </div>
                
                <div class="item-desc">Relax prostatic smooth muscle (tamsulosin, alfuzosin, silodosin).</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    5-Alpha Reductase Inhibitors
                    
                </div>
                
                <div class="item-desc">Shrink prostate over months (finasteride, dutasteride).</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Combination Therapy
                    
                </div>
                
                <div class="item-desc">Alpha-blocker plus 5-ARI for larger prostates.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    PDE5 Inhibitors
                    
                </div>
                
                <div class="item-desc">Tadalafil approved for BPH and erectile dysfunction.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    TURP
                    
                </div>
                
                <div class="item-desc">Transurethral resection, gold standard surgical treatment.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Laser Procedures
                    
                </div>
                
                <div class="item-desc">HoLEP, PVP for surgical candidates.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Minimally Invasive Therapies
                    
                </div>
                
                <div class="item-desc">UroLift, Rezum for selected patients.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    ROCK Inhibitors (Experimental)
                    
                </div>
                
                <div class="item-desc">Y-27632 and GSK269962A target ROCK1/2 to reduce fibrosis, EMT, and proliferation.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/39455522" target="_blank">PMID:39455522</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"At the in vivo level, Y-27632 reversed prostatic hyperplasia and fibrosis in BPH model rats to some extent."</div>
                
                
                <div class="evidence-explanation">This evidence demonstrates therapeutic potential of ROCK inhibition in reversing BPH pathology in animal models.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38711089" target="_blank">PMID:38711089</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Inhibition of ROCK1 activation suppressed MSC migration and their potential for stromal differentiation."</div>
                
                
                <div class="evidence-explanation">This evidence shows ROCK1 inhibition (GSK269962A) prevents stromal hyperplasia by blocking MSC recruitment and differentiation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Antioxidant Therapy (Experimental)
                    
                </div>
                
                <div class="item-desc">Anethole trithione (ATT) inhibits mitochondrial ROS to reduce proliferation and stemness.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37827216" target="_blank">PMID:37827216</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In human BPH-1 epithelial cells, ATT decreased mitochondrial metabolism, cell proliferation, and stemness features."</div>
                
                
                <div class="evidence-explanation">This evidence demonstrates antioxidant therapy can reduce key pathogenic features of BPH epithelial cells.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">üåç</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Age</div>
                
                <div class="item-desc">Primary risk factor, rare before 40</div>
                
                
                
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Obesity</div>
                
                <div class="item-desc">Associated with larger prostate volume</div>
                
                
                
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Diabetes</div>
                
                <div class="item-desc">Associated with BPH</div>
                
                
                
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Physical Inactivity</div>
                
                <div class="item-desc">Increases risk</div>
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    PSA
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Variable)</span>
                    
                </div>
                
                <div class="item-desc">Context: May be mildly elevated in BPH</div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Testosterone
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Normal)</span>
                    
                </div>
                
                <div class="item-desc">Context: Serum testosterone usually normal</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Benign Prostatic Hyperplasia
category: Complex
parents:
- Urological Disease
disease_term:
  preferred_term: benign prostatic hyperplasia
  term:
    id: MONDO:0010811
    label: benign prostatic hyperplasia
pathophysiology:
- name: Prostatic Stromal and Epithelial Proliferation
  description: &gt;
    Age-related increase in prostatic stromal and glandular tissue,
    particularly in the transition zone. Dihydrotestosterone (DHT)
    drives proliferation through androgen receptors.
  cell_types:
  - preferred_term: Prostatic Epithelial Cell
    term:
      id: CL:0002231
      label: epithelial cell of prostate
  biological_processes:
  - preferred_term: Cell Proliferation
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:38654277
    supports: SUPPORT
    snippet: &#34;Proliferative nodular formation represents a characteristic pathological feature of benign prostatic hyperplasia (BPH) and serves as the primary cause for prostate volume enlargement and consequent lower urinary tract symptoms (LUTS).&#34;
    explanation: This evidence confirms that proliferative nodular formation in the transition zone is the primary pathological feature driving BPH symptoms.
- name: Bladder Outlet Obstruction
  description: &gt;
    Enlarged prostate compresses urethra, increasing resistance to
    urine flow. Static component from tissue mass and dynamic
    component from smooth muscle tone.
- name: Detrusor Dysfunction
  description: &gt;
    Chronic obstruction leads to detrusor muscle hypertrophy and
    later decompensation. Results in overactive bladder symptoms
    and incomplete emptying.
  cell_types:
  - preferred_term: Smooth Muscle Cell
    term:
      id: CL:0000192
      label: smooth muscle cell
  evidence:
  - reference: PMID:37827216
    supports: SUPPORT
    snippet: &#34;Benign prostate hyperplasia (BPH) is caused by the nonmalignant enlargement of the transition zone of the prostate gland, leading to lower urinary tract symptoms.&#34;
    explanation: This evidence supports that BPH-related enlargement causes lower urinary tract symptoms through bladder outlet obstruction and detrusor dysfunction.
- name: Androgen-Dependent Growth
  description: &gt;
    DHT converted from testosterone by 5-alpha reductase drives
    prostatic growth. 5-alpha reductase inhibitors shrink prostate.
  biological_processes:
  - preferred_term: Androgen Response
    term:
      id: GO:0030521
      label: androgen receptor signaling pathway
- name: Hypoxia-Induced Epithelial-Mesenchymal Transition
  description: &gt;
    Hypoxic basal epithelial cells (BE5) drive nodular formation through
    upregulation of FOS and activation of EMT signaling, particularly in
    glandular nodules of the transition zone.
  biological_processes:
  - preferred_term: Epithelial to Mesenchymal Transition
    term:
      id: GO:0001837
      label: epithelial to mesenchymal transition
  evidence:
  - reference: PMID:38654277
    supports: SUPPORT
    snippet: &#34;A distinct subgroup of basal epithelial (BE) cells, referred to as BE5, was identified to play a crucial role in driving this progression through the hypoxia-induced epithelial-mesenchymal transition (EMT) signaling pathway.&#34;
    explanation: This evidence identifies BE5 cells as key drivers of BPH through hypoxia-induced EMT, establishing a molecular mechanism for nodular formation.
- name: TGF-beta/ROCK1 Mediated Stromal Hyperplasia
  description: &gt;
    Aberrant activation of TGF-beta/ROCK1 pathway recruits mesenchymal
    stem cells that differentiate into fibroblasts and myofibroblasts,
    driving stromal hyperplasia and fibrosis.
  biological_processes:
  - preferred_term: TGF-beta Signaling
    term:
      id: GO:0007179
      label: transforming growth factor beta receptor signaling pathway
  evidence:
  - reference: PMID:38711089
    supports: SUPPORT
    snippet: &#34;The aberrant activation of transforming growth factor Œ≤ (TGF-Œ≤)/Rho kinase 1 (ROCK1) increased the stemness of BPH tissue by recruiting mesenchymal stem cells (MSCs), indicating the important role of embryonic reawakening in BPH.&#34;
    explanation: This evidence demonstrates that TGF-beta/ROCK1 activation drives prostatic stromal hyperplasia through MSC recruitment and differentiation.
  - reference: PMID:39455522
    supports: SUPPORT
    snippet: &#34;ROCK1 and ROCK2 were significantly up-regulated in BPH tissues, correlating with clinical parameters.&#34;
    explanation: This evidence confirms upregulation of ROCK1/2 in human BPH tissues and their correlation with disease severity.
- name: ROCK-Mediated Fibrosis and Beta-Catenin Signaling
  description: &gt;
    ROCK1/2 activation promotes fibrosis, EMT, and cell proliferation by
    stabilizing beta-catenin and activating downstream targets including
    C-MYC, Snail, and Survivin. ROCK inhibition reverses these processes.
  biological_processes:
  - preferred_term: Wnt Signaling Pathway
    term:
      id: GO:0016055
      label: Wnt signaling pathway
  evidence:
  - reference: PMID:39455522
    supports: SUPPORT
    snippet: &#34;ROCK downregulation inhibited the Œ≤-catenin signaling pathway (such as C-MYC, Snail and Survivin) and decreased Œ≤-catenin protein stability, while inhibiting TGF-Œ≤/Smad2/3 signaling.&#34;
    explanation: This evidence shows ROCK signaling converges on beta-catenin pathway to drive BPH pathophysiology, providing a therapeutic target.
- name: Oxidative Stress and Epithelial Plasticity
  description: &gt;
    Low-androgen signaling epithelial populations show increased vulnerability
    to oxidative stress due to reduced antioxidant defenses. Mitochondrial
    ROS drives cell proliferation and stemness in BPH.
  biological_processes:
  - preferred_term: Response to Oxidative Stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  evidence:
  - reference: PMID:37827216
    supports: SUPPORT
    snippet: &#34;Pb-PRL mouse prostates exhibited increased vulnerability to oxidative stress due to reduction of antioxidant enzyme expression. One-month treatment of Pb-PRL mice with anethole trithione (ATT), a specific inhibitor of mitochondrial ROS production, reduced prostate weight and voiding frequency.&#34;
    explanation: This evidence demonstrates that oxidative stress contributes to BPH progression and that antioxidant therapy can reduce prostate enlargement and symptoms.
- name: Inflammation and IL-6 Signaling
  description: &gt;
    Periodontal pathogens and inflammatory stimuli upregulate IL-6, IL-6R,
    and gp130, activating the Akt pathway to promote epithelial and stromal
    proliferation while inhibiting apoptosis.
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:38764065
    supports: SUPPORT
    snippet: &#34;P. gingivalis infection promoted prostate cell proliferation, inhibited apoptosis, and upregulated the expression of inflammatory cytokines interleukin-6 (IL-6; 4.47-fold), interleukin-6 receptor-Œ± (IL-6RŒ±; 5.74-fold) and glycoprotein 130 (gp130; 4.47-fold) in prostatic tissue.&#34;
    explanation: This evidence links oral-prostate inflammation to BPH progression through IL-6/IL-6R/gp130-mediated Akt signaling, representing a novel pathophysiological axis.
phenotypes:
- name: Urinary Frequency
  category: Urological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Urinary Frequency
    term:
      id: HP:0000012
      label: Urinary urgency
- name: Nocturia
  category: Urological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Nocturia
    term:
      id: HP:0000017
      label: Nocturia
  evidence:
  - reference: PMID:37827216
    supports: SUPPORT
    snippet: &#34;One-month treatment of Pb-PRL mice with anethole trithione (ATT), a specific inhibitor of mitochondrial ROS production, reduced prostate weight and voiding frequency.&#34;
    explanation: This evidence shows that voiding frequency (including nocturia) is a key symptom of BPH that can be reduced through therapeutic intervention targeting oxidative stress.
- name: Weak Urinary Stream
  category: Urological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Weak Stream
    term:
      id: HP:0000016
      label: Urinary retention
- name: Hesitancy
  category: Urological
  frequency: FREQUENT
  notes: Difficulty initiating urination
  phenotype_term:
    preferred_term: Urinary Hesitancy
    term:
      id: HP:0000016
      label: Urinary retention
- name: Incomplete Emptying
  category: Urological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Incomplete Emptying
    term:
      id: HP:0000016
      label: Urinary retention
- name: Urinary Retention
  category: Urological
  frequency: OCCASIONAL
  notes: Acute retention is emergency
  phenotype_term:
    preferred_term: Urinary Retention
    term:
      id: HP:0000016
      label: Urinary retention
biochemical:
- name: PSA
  presence: Variable
  context: May be mildly elevated in BPH
- name: Testosterone
  presence: Normal
  context: Serum testosterone usually normal
genetic:
- name: SRD5A2
  association: Risk Factor
  notes: 5-alpha reductase
- name: AR
  association: Risk Factor
  notes: Androgen receptor CAG repeats
- name: ROCK1
  association: Causal
  notes: Rho-associated kinase 1, upregulated in BPH, drives fibrosis and EMT
  evidence:
  - reference: PMID:39455522
    supports: SUPPORT
    snippet: &#34;ROCK1 and ROCK2 were significantly up-regulated in BPH tissues, correlating with clinical parameters.&#34;
    explanation: This evidence establishes ROCK1 as causally implicated in BPH pathogenesis through upregulation and correlation with disease severity.
- name: ROCK2
  association: Causal
  notes: Rho-associated kinase 2, upregulated in BPH, promotes proliferation and fibrosis
  evidence:
  - reference: PMID:39455522
    supports: SUPPORT
    snippet: &#34;Y-27632 targeted the inhibition of ROCK1 &amp; ROCK2 expression and inhibited cell proliferation, fibrosis, epithelial-mesenchymal transition (EMT), while induced cell apoptosis in a dose-dependent manner.&#34;
    explanation: This evidence demonstrates ROCK2 as a causal factor in BPH through its role in proliferation, fibrosis, and EMT.
- name: FOS
  association: Causal
  notes: c-Fos transcription factor, upregulated in hypoxic BE5 cells, drives EMT
  evidence:
  - reference: PMID:38654277
    supports: SUPPORT
    snippet: &#34;A distinguishing characteristic of the BE5 cell subgroup in patients with BPH was its heightened hypoxia and upregulated expression of FOS.&#34;
    explanation: This evidence identifies FOS upregulation as a key molecular driver of hypoxia-induced EMT in BPH nodular formation.
environmental:
- name: Age
  notes: Primary risk factor, rare before 40
- name: Obesity
  notes: Associated with larger prostate volume
- name: Diabetes
  notes: Associated with BPH
- name: Physical Inactivity
  notes: Increases risk
treatments:
- name: Alpha-Blockers
  description: Relax prostatic smooth muscle (tamsulosin, alfuzosin, silodosin).
- name: 5-Alpha Reductase Inhibitors
  description: Shrink prostate over months (finasteride, dutasteride).
- name: Combination Therapy
  description: Alpha-blocker plus 5-ARI for larger prostates.
- name: PDE5 Inhibitors
  description: Tadalafil approved for BPH and erectile dysfunction.
- name: TURP
  description: Transurethral resection, gold standard surgical treatment.
- name: Laser Procedures
  description: HoLEP, PVP for surgical candidates.
- name: Minimally Invasive Therapies
  description: UroLift, Rezum for selected patients.
- name: ROCK Inhibitors (Experimental)
  description: Y-27632 and GSK269962A target ROCK1/2 to reduce fibrosis, EMT, and proliferation.
  evidence:
  - reference: PMID:39455522
    supports: SUPPORT
    snippet: &#34;At the in vivo level, Y-27632 reversed prostatic hyperplasia and fibrosis in BPH model rats to some extent.&#34;
    explanation: This evidence demonstrates therapeutic potential of ROCK inhibition in reversing BPH pathology in animal models.
  - reference: PMID:38711089
    supports: SUPPORT
    snippet: &#34;Inhibition of ROCK1 activation suppressed MSC migration and their potential for stromal differentiation.&#34;
    explanation: This evidence shows ROCK1 inhibition (GSK269962A) prevents stromal hyperplasia by blocking MSC recruitment and differentiation.
- name: Antioxidant Therapy (Experimental)
  description: Anethole trithione (ATT) inhibits mitochondrial ROS to reduce proliferation and stemness.
  evidence:
  - reference: PMID:37827216
    supports: SUPPORT
    snippet: &#34;In human BPH-1 epithelial cells, ATT decreased mitochondrial metabolism, cell proliferation, and stemness features.&#34;
    explanation: This evidence demonstrates antioxidant therapy can reduce key pathogenic features of BPH epithelial cells.
datasets:
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Benign_Prostatic_Hyperplasia.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>